Amphastar Pharmaceuticals saw no growth in patent filings and highest growth of 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Amphastar Pharmaceuticals‘s patent filings and grants. Buy the databook here.
Amphastar Pharmaceuticals has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 100% of grants. The European Patent Office(EPO) patent Office are among the top ten patent offices where Amphastar Pharmaceuticals is filings its patents. Among the top granted patent authorities, Amphastar Pharmaceuticals has 100% of its grants in European Patent Office(EPO).
Hanmi Science and Novo Nordisk Foundation could be the strongest competitors for Amphastar Pharmaceuticals
Caries related patents lead Amphastar Pharmaceuticals portfolio
Amphastar Pharmaceuticals has highest number of patents in caries.
For comprehensive analysis of Amphastar Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.